Cargando…
CARDIOVASCULAR DISEASES AND ANDROGEN DEPRIVATION THERAPY
The leading cause of death in patients with prostate cancer are cardiovascular diseases. Androgen deprivation therapy is the mainstay of treatment in prostate cancers. The latter has numerous perplexed disadvantaging effects to cardiovascular health. ADT alternates the metabolic profile, insulin res...
Autor principal: | Boban, Marko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sestre Milosrdnice University Hospital and Institute of Clinical Medical Research, Vinogradska cesta c. 29 Zagreb
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693560/ https://www.ncbi.nlm.nih.gov/pubmed/34975199 http://dx.doi.org/10.20471/acc.2019.58.s2.09 |
Ejemplares similares
-
WHICH PATIENTS WILL BENEFIT MOST FROM DOCETAXEL ADDITION TO ANDROGEN DEPRIVATION THERAPY (ADT) IN METASTATIC CASTRATE-SENSITIVE PROSTATE CANCER (MCSPC)?
por: Gamulin, Marija, et al.
Publicado: (2019) -
WHO SHOULD RECEIVE NOVEL HORMONAL THERAPY WITH ANDROGEN DEPRIVATION THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER?
por: Omrčen, Tomislav
Publicado: (2019) -
ROLE OF ANDROGEN RECEPTOR-TARGETED AGENTS IN LOCALIZED PROSTATE CANCER
por: Murgić, Jure, et al.
Publicado: (2022) -
Androgen Deprivation Therapy–Induced Cardiovascular Disease
por: Dhanushkodi, Manikandan
Publicado: (2016) -
Androgen Deprivation Therapy and Cardiovascular Risk
por: Mourmouris, Panagiotis, et al.
Publicado: (2012)